PER
Click for more information
0.00% 8.0¢ percheron therapeutics limited

Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD, page-60

  1. MrLearner
    763 Posts.
    lightbulb Created with Sketch. 207
    clock Created with Sketch.
    24/08/20
    16:44
    Post #: 46775229
    Have to agree with you on this point Andy.

    I have positions in MSB and IMU. Their management teams are excellent and their CEO's are superb with both experts at the science behind their products. Both are also extremely articulate. MSB's CEO was brilliant in a recent ODAC meeting to get a 9-1 approval for Remestemcell-L
    ANP Price at posting: 9.8¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 6  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

WR1 Stock watchers charged up by Winsome Resources' latest lithium drilling results
right-arrow Created with Sketch.
NOX Noxopharm aims for autoimmune market with first human trial of SOF-SKN
right-arrow Created with Sketch.
MBK Metal Bank setting up shop in Saudi Arabia as part of MENA expansion plans
right-arrow Created with Sketch.
NEWS Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more
right-arrow Created with Sketch.
UNT UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off
right-arrow Created with Sketch.
SUM Summit Minerals jumps 6% as LiDAR survey boosts confidence in niobium mineralisation
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $72.12M
Open High Low Value Volume
8.1¢ 8.1¢ 7.9¢ $142.6K 1.782M

Buyers (Bids)

No. Vol. Price($)
1 100000 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 1335 1
View Market Depth
Last trade - 16.10pm 20/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.